September is Prostate Cancer Awareness Month
We can help you tackle prostate cancer head on as the only specialty pharmacy 100% focused on cancer care. Our personalized services include medication adherence and side effect management programs created by expert Board-Certified Oncology pharmacists – and the highest clinical and compassionate care possible.
A Play-by-Play About Prostate Cancer
According to the American Cancer Society, other than skin cancer, prostate cancer is the most common cancer in American men. In 2023, It is estimated that about 288,000 new cases will be diagnosed.1
Almost all prostate cancers are adenocarcinomas, which is a cancer that forms in a gland and can spread to other areas of the body. Other types of cancer that can start in the prostate include:
- Small cell carcinomas
- Neuroendocrine tumors (other than small cell carcinomas)
- Transitional cell carcinomas
- Sarcomas
Risk Factors
Age - about 6 cases in 10 diagnosed are 65 or older, with an average age of 66
Race/Ethnicity – African American men and Caribbean men of African ancestry are at a higher risk
Geography – most common in North America, northwestern Europe, Australia, and on Caribbean islands
Family history – Family history can increase your risk. For example, having a father or brother with prostate cancer can more than double the risk.
Why Huddle with Onco360?
- As a specialty pharmacy 100% focused on cancer, we will act as your advocate with your physician, insurance company, and others involved in your treatment.
- Timing is crucial when it comes to cancer treatment. Our goal, without prior authorization or funding issues, is to have your medication delivered within 3-4 days. We even provide complimentary overnight shipping to your doorstep.
- With our innovative and personalized Prostate Medication Therapy Management Programs, we will make sure you understand your medications, their dosage, and any potential side effects. Our pharmacists are on call 24/7 if you have any issues at 877.662.6633.
- Our Team of OncoAdvocates® explores funding options for qualified patients quickly with our proprietary Funding FastTrack program.
|
Last year, Onco360 |
88% of our prostate cancer patients paid less than $50 out-of-pocket for |
Currently, 76% of our prostate cancer patients’ copays are covered by funding sources |
Onco360 dispenses these medications to treat prostate cancer.
Casodex® (bicalutamide)
Deltasone (prednisone)
Erleada® (apalutamide)
Firmagon® (degarelix)
Jevtana® (cabazitaxel)
Keytruda® (pembrolizumab)
Lupron® (leuprolide)
Medrol (methylprednisolone)
Nilandron® (nilutamide)
Novantrone® (mitoxantrone)
Nubeqa® (darolutamide)
Orgovyx® (relugolix)
Paraplatin® (carboplatin)
Platinol® (cisplatin)
Taxotere® (doxetaxel)
Toposar® (etoposide)
Trelstar® (triptorelin)
Xgeva (denosumab)
Xtandi® (enzalutamide)
Yonsa® (abiraterone acetate, micronized)
Zoladex® (goserelin)
Zometa (zoledronic acid)
Zytiga® (abiraterone acetate)
****This list is a small portion of the comprehensive medications Onco360 can provide.
If you are a provider and would like to refer to Onco360, click below
Helpful Resources:
1What is Prostate Cancer. July 31, 2023. Accessed July 31, 2023 https://www.cancer.org/cancer/types/prostate-cancer/about/what-is-prostate-cancer.html https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
*2023 nomination by MMIT in the Independent Specialty Pharmacy category. MMITnetwork.com